secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001104659-24-067446
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics reports Phase 1 ELiPSE-1 data: 30% CRR, 40% ORR in R/R NHL; no DLTs
--------------------------------------------------------------------------------

- As of March 27, 2024, 12 patients evaluable for safety; no DLTs or GvHD observed; most cycles outpatient.
- Across all dose levels (10 evaluable), 30% complete response rate and 40% objective response rate.
- At Schedule A dose levels 300M and 1B cells, 40% CRR and 60% ORR in 5 heavily pre-treated patients.
- Novel cfDNA assay suggests CNTY-101 persists in tissues; AUC trends with dose.
- Dose escalation continues at DL3B (3 weekly infusions of 1B cells) and DL4A (single 3B cells).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924067446/0001104659-24-067446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924067446/tm2416244d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-067446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer